Cargando…

Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis

OBJECTIVE: To outline the pharmacodynamics, efficacy and safety of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. QUALITY OF EVIDENCE: MEDLINE database was searched to review recent pharmacodynamic and clinical studies evaluating besifloxacin and comparing besi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khimdas, S., Visscher, K.L., Hutnik, C.M.L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661456/ https://www.ncbi.nlm.nih.gov/pubmed/23861618 http://dx.doi.org/10.4137/OED.S4102

Ejemplares similares

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein, Bruce E, et al.
Publicado: (2012)

Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
por: Sanfilippo, Christine M., et al.
Publicado: (2017)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
por: Haas, Wolfgang, et al.
Publicado: (2011)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
por: Morris, Timothy W, et al.
Publicado: (2011)

The Safety of Besifloxacin Ophthalmic Suspension 0.6 % Used Three Times Daily for 7 Days in the Treatment of Bacterial Conjunctivitis
por: Malhotra, Ranjan, et al.
Publicado: (2013)

Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6%
por: DeCory, Heleen H., et al.
Publicado: (2020)

Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
por: Comstock, Timothy L, et al.
Publicado: (2010)

Safety of Besifloxacin Ophthalmic Suspension 0.6% in Cataract and LASIK Surgery Patients
por: Majmudar, Parag A., et al.
Publicado: (2014)

Characterization of Polybacterial versus Monobacterial Conjunctivitis Infections in Pediatric Subjects Across Multiple Studies and Microbiological Outcomes with Besifloxacin Ophthalmic Suspension 0.6%
por: Blondeau, Joseph M, et al.
Publicado: (2021)

Besifloxacin Nanocrystal: Towards an Innovative Ophthalmic Preparation
por: de Jesus, José Izo Santana da Silva, et al.
Publicado: (2022)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients
por: Nielsen, Steven A, et al.
Publicado: (2013)

Bacterial conjunctivitis
por: Hutnik, Cindy, et al.
Publicado: (2010)

Safety of besifloxacin ophthalmic suspension 0.6% in refractive surgery: a retrospective chart review of post-LASIK patients [Corrigendum]
Publicado: (2013)

Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones
por: Haas, Wolfgang, et al.
Publicado: (2013)

Besifloxacin: Efficacy and Safety in Treatment and Prevention of Ocular Bacterial Infections
por: Mah, Francis S., et al.
Publicado: (2016)

Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study
por: Malhotra, Ranjan, et al.
Publicado: (2012)

Nano-Formulating Besifloxacin and Employing Quercetin as a Synergizer to Enhance the Potency of Besifloxacin against Pathogenic Bacterial Strains: A Nano-Synergistic Approach
por: Al Hagbani, Turki, et al.
Publicado: (2023)

A randomized controlled trial of povidone-iodine/dexamethasone ophthalmic suspension for acute viral conjunctivitis
por: Pepose, Jay S, et al.
Publicado: (2019)

Clinical use of gatifloxacin ophthalmic solution for treatment of bacterial conjunctivitis
por: Cervantes, Lorenzo J, et al.
Publicado: (2011)

Gatifloxacin Ophthalmic Solution for Treatment of Bacterial Conjunctivitis: Safety, Efficacy and Patient Perspective
por: Schultz, Clyde
Publicado: (2012)

Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration
por: Torkildsen, Gail, et al.
Publicado: (2010)

Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension
por: Gaynes, Bruce I, et al.
Publicado: (2008)

Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae
por: Haas, Wolfgang, et al.
Publicado: (2010)

Besifloxacin liposomes with positively charged additives for an improved topical ocular delivery
por: dos Santos, Giselly Almeida, et al.
Publicado: (2020)

Development and Validation of Different Ultraviolet-Spectrophotometric Methods for the Estimation of Besifloxacin in Different Simulated Body Fluids
por: Singh, C. L., et al.
Publicado: (2015)

Olopatadine ophthalmic solution suppresses substance P release in the conjunctivitis models
por: Tamura, Tadafumi
Publicado: (2012)

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%
por: Bergmann, Mark T, et al.
Publicado: (2014)

Impact of Ophthalmic Viscosurgical Devices in Cataract Surgery
por: Malvankar-Mehta, Monali S., et al.
Publicado: (2020)

In Vitro Time-Kill of Common Ocular Pathogens with Besifloxacin Alone and in Combination with Benzalkonium Chloride
por: Blondeau, Joseph, et al.
Publicado: (2021)

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
por: Bucci, Frank A, et al.
Publicado: (2015)

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
por: Chigbu, DeGaulle I, et al.
Publicado: (2015)

Special Senses: Ophthalmic Changes in Chlorosis, Pernicious Anæmia and Leucocythæmia—Phlyctenular Conjunctivitis, &c.
por: Maynard, F. P.
Publicado: (1898)

Evaluation of dacryocystorhinostomy using optical coherence tomography and rebamipide ophthalmic suspension
por: Fujimoto, Masahiro, et al.
Publicado: (2014)

Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopenia
por: Profit, Louise
Publicado: (2006)

In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
por: Sheppard, John D., et al.
Publicado: (2018)

Ophthalmic Therapeutics
Publicado: (1882)

Dose Uniformity of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38% Compared with Prednisolone Acetate Ophthalmic Suspension 1%
por: Marlowe, Zora T., et al.
Publicado: (2021)

Therapeutic Targets in Allergic Conjunctivitis
por: Labib, Bisant A., et al.
Publicado: (2022)

Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
por: Williams, Patricia B, et al.
Publicado: (2010)

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis
por: Cavet, Megan E, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1l9vo2j6culigg7iahpdlm8k15